Previous 10 | Next 10 |
Disco Corporation ADR (DSCSY) is expected to report for Q2 2024 Sonic Foundry Inc. (SOFO) is expected to report for quarter end 2023-09-30 Sono Group N.V. (SEVCQ) is expected to report for quarter end 2023-09-30 Minim Inc (MINM) is expected to report for Q3 2023 Enel Spa ADR (ENLA...
Enel Spa ADR (ENLAY) is expected to report for Q3 2023 LEG Immobilien SE Registered Shares (LEGIF) is expected to report for Q3 2023 G. Willi-Food International Ltd. (WILC) is expected to report for Q3 2023 Worthington Steel Inc. (WS) is expected to report $0.15 for Q2 2024 Sonic ...
2023-12-15 17:36:27 ET More on Kazia Kazia Therapeutics falls after announcing $2M direct offering Kazia stock jumps after proposed license deal for paxalisib outside oncology Historical earnings data for Kazia Financial information for Kazia For furt...
IMV Inc. (IMVIQ) is expected to report for Q3 2023 Orbit International Corp. (ORBT) is expected to report for quarter end 2023-09-30 PLx Pharma Winddown Corp. (PLXPQ) is expected to report for quarter end 2023-09-30 Advantage Energy Ltd (AAVVF) is expected to report for Q1 2024 We...
lululemon athletica inc. (LULU) is expected to report $2.27 for Q3 2024 Arco Platform Limited (ARCE) is expected to report $-0.17 for Q3 2023 Elekta AB ADR (EKTAY) is expected to report for Q2 2024 Kimberly - Clark de Mexico S.A. ADR (KCDMY) is expected to report for Q1 2024 Torri...
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering PR Newswire SYDNEY , Dec. 5, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced the...
2023-12-01 09:04:12 ET More on Kazia Kazia stock jumps after proposed license deal for paxalisib outside oncology Kazia issues update on paxalisib study in CNS lymphoma patients For further details see: Kazia Therapeutics falls after announcing $2M direct offering
Kazia Therapeutics Announces $2 Million Registered Direct Offering PR Newswire SYDNEY , Dec. 1, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it h...
Veradigm Inc. (MDRX) is expected to report $0.17 for Q3 2023 Aperam SA New York Shares (APEMY) is expected to report for Q3 2023 HTG Molecular Diagnostics Inc. (HTGMQ) is expected to report for Q3 2023 Enel Spa ADR (ENLAY) is expected to report for Q3 2023 Firm Capital Property Tr...
2023-11-29 07:49:55 ET Kazia Therapeutics ( NASDAQ: KZIA ) has signed a non-binding letter of intent with an undisclosed biotech firm for the proposed granting of worldwide rights to develop and commercialize its lead candidate, paxalisib, in an indication outside of cancer. ...
News, Short Squeeze, Breakout and More Instantly...
Kazia Therapeutics Limited Company Name:
KZIA Stock Symbol:
NASDAQ Market:
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS PR Newswire SYDNEY , May 1, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased t...
Shares of NextPlat Corp (NASDAQ: NXPL) rose sharply in today’s pre-market trading after the company reported consolidated 2023 revenues of $...
Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-q...